Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Imatinib mesylate | 100mg Pack Size. Group: Bioactive Small Molecules, Research Organics & Inorganics. Formula: C29H31N7O ยท CH4O3S. CAS No. 220127-57-1. Prepack ID 60579435-100mg. Molecular Weight 589.71. See USA prepack pricing. |  |
| Imatinib Mesylate | Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit , Bcr-Abl , and PDGFR ( IC 50 =100 nM) tyrosine kinases. Uses: Scientific research. Group: Signaling pathways. Alternative Names: STI571 Mesylate; CGP-57148B Mesylate. CAS No. 220127-57-1. Pack Sizes: 10 mM * 1 mL; 200 mg; 500 mg; 1 g; 5 g. Product ID: HY-50946. |  |
| Imatinib Mesylate | Imatinib Mesylate. Uses: For analytical and research use. Group: Impurity standards. CAS No. 220127-57-1. Molecular Formula: C30H35N7O4S. Mole Weight: 589.71. Catalog: APB220127571. |  |
| 17-AAG hydrochloride | 17-AAG hydrochloride is a potent HSP90 inhibitor with IC50 value of 5 nM, which is a 100-fold higher binding affinity for HSP90 derived from tumour cells than that from normal cells. It is less toxic by binding to Hsp90 and altering its function. It causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells. It has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively. It displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice compared with that from the normal tissues in vivo. Uses: 17-aag hydrochloride has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant t315i and e255k bcr-abl mutants. Synonyms: 17-AAG hydrochloride; 17 AAG hydrochloride; 17AAG hydrochloride; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate hydrochloride;Tanespimycin Hydrochloride;NSC 330507 Hydrochloride;CP 127374 Hydrochloride;17-(Allylamino)-17-desmethylgeldanamycin hydrochloride. Grades: >98%. CAS No. 911710-03-7. Molecular formula: C31H44ClN3O8. Mole weight: 622.15. |  |
| Bafetinib | A substituted benzamide derivative structurally related to STI-571 (Imatinib Mesylate). It was identified as highly potent Bcr-Abl kinase inhibitor. Group: Biochemicals. Alternative Names: N-[3- ([4, 5'-Bipyrimidin]-2-ylamino) -4-methylphenyl]-4-[[ (3S) -3- (dimethylamino) -1-pyrrolidinyl]methyl]-3- (trifluoromethyl) benzamide; INNO 406; NS 187. Grades: Highly Purified. CAS No. 859212-16-1. Pack Sizes: 1mg. US Biological Life Sciences. |  Worldwide |
| CGP 76030 | CGP76030 is a ual-specific Src and Abl kinase inhibitor, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Uses: Ual-specific src and abl kinase inhibitor. Synonyms: CGP-76030; CGP76030; CGP76030; CGP-076030. 7-(4-(2-((2-methoxyethyl)amino)ethoxy)phenyl)-5-(3-methoxyphenyl)-7H-Pyrrolo(2,3-d)pyrimidin-4-amine. Grades: ≥98%. CAS No. 497152-38-2. Molecular formula: C24H27N5O3. Mole weight: 433.5. | |
| Flumatinib Mesylate | Flumatinib mesylate, a derivative of imatinib, is a multi-kinase inhibitor for c-Abl, PDGFRβ and c-Kit. It is currently in Phase I and II clinical trials in China for the treatment of chronic myelogenous leukemia (CML). It effectively overcomes drug resistance of certain KIT mutants. It can reduce the expression of C-MYC, HIF-1 α and VEGF in U266 cell line in a time- and dose-dependent manners. Synonyms: HH-GV-678 mesylate. Grades: >98%. CAS No. 895519-91-2. Molecular formula: C30H33F3N8O4S. Mole weight: 658.69. | |
| Imatinib, Methanesulfonate Salt (STI-571, CGP-57148B) | A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Imatinib inhibits bcr-abl tyrosine kinase activity, upon which some types of tumor cells depend for growth. Imatinib acts by binding to the ATP binding site of bcr-abl and competitively inhibiting its tyrosine kinase activity. Imatinib is selective for bcr-abl, but it also targets several other kinases (c-kit and PDGF-R). (1). Group: Biochemicals. Alternative Names: 4- [ (4-Methyl-1-piperazinyl) methyl] -N- [4-methyl-3- [ [4- (3-pyridinyl) -2-pyrimidinyl] amino] phenyl] benzamide Methanesulfonate; CGP 57148B; Imatinib Mesilate; Imatinib Methanesulfonate; Imatinib Mesylate; STI 571; Bcr-abl Inhibitor IV; Abl Inhibitor V, PDGFR Tyrosine Kinase Inhibitor XXIV, c-Kit Inhibitor IV. Grades: Highly Purified. CAS No. 220127-57-1. Pack Sizes: 25mg, 1g, 5g, 10g. US Biological Life Sciences. | Worldwide |
| PD166326 | PD166326 is one of the most potent members of the pyridopyrimidine class of protein tyrosine kinase inhibitors. In mice with the CML-like disease, PD166326 rapidly inhibited Bcr/Abl kinase activity after a single oral dose and demonstrated marked antileukemic activity in vivo. In vivo, PD166326 was also superior to imatinib mesylate in inhibiting the constitutive tyrosine phosphorylation of numerous leukemia-cell proteins, including the src family member Lyn. PD166326 also prolonged the survival of mice with imatinib mesylate-resistant CML induced by the Bcr/Abl mutants P210/H396P and P210/M351T. Synonyms: PD-166326; PD 166326; 6-(2,6-Dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one. CAS No. 185039-91-2. Molecular formula: C21H16Cl2N4O2. Mole weight: 427.28. | |
Our database is helping our users find suppliers everyday.
